We can help you identify which compounds have the optimal safety profile to advance into the clinic. Our experience extends from early discovery through to the clinic so we have a full picture of the entire drug discovery and development continuum and can support you at every stage of your project. The scientific expertise and capabilities can be accessed as fee-for-services or as part of partially or fully integrated programs.

Drug toxicity is a key reason for drug attrition. Identifying potential toxicity and understanding mechanisms of toxicity at an early stage in drug discovery can save both time and developmental costs, and allows the safest compounds to be progressed into preclinical development. As a consequence, human relevant cell-based models are being introduced in drug discovery to address this need. Evotec and wholly owned subsidiary Cyprotex are leading the science in this field and have significant expertise in the latest techniques such as high content imaging, microelectrode array, 3D cell and iPSC-derived models and transcriptomics.

Regulatory safety studies are still an important part of the preclinical drug development process and are a requirement prior to an investigational drug reaching the clinic. Evotec’s Safety Assessment offers a full range of services from exploratory programs to fully GLP-compliant toxicology studies. These can be performed either as standalone services or part of a fully integrated preclinical development package.